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DNA damage response and DNA repair – dog as
a model?
Nicole Grosse1,2, Barbara van Loon2† and Carla Rohrer Bley1*†
Abstract
Background: Companion animals like dogs frequently develop tumors with age and similarly to human
malignancies, display interpatient tumoral heterogeneity. Tumors are frequently characterized with regard to their
mutation spectra, changes in gene expression or protein levels. Among others, these changes affect proteins
involved in the DNA damage response (DDR), which served as a basis for the development of numerous clinically
relevant cancer therapies. Even though the effects of different DNA damaging agents, as well as DDR kinetics, have
been well characterized in mammalian cells in vitro, very little is so far known about the kinetics of DDR in tumor
and normal tissues in vivo.
Discussion: Due to (i) the similarities between human and canine genomes, (ii) the course of spontaneous tumor
development, as well as (iii) common exposure to environmental agents, canine tumors are potentially an excellent
model to study DDR in vivo. This is further supported by the fact that dogs show approximately the same rate of
tumor development with age as humans. Though similarities between human and dog osteosarcoma, as well as
mammary tumors have been well established, only few studies using canine tumor samples addressed the
importance of affected DDR pathways in tumor progression, thus leaving many questions unanswered.
Summary: Studies in humans showed that misregulated DDR pathways play an important role during tumor
development, as well as in treatment response. Since dogs are proposed to be a good tumor model in many
aspects of cancer research, we herein critically investigate the current knowledge of canine DDR and discuss (i) its
future potential for studies on the in vivo level, as well as (ii) its possible translation to veterinary and human
medicine.
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Background
Mutations in important driver genes, arising from various
defects in the DNA damage response (DDR) pathways,
can influence the tumor response to treatment. Hence,
affected DDR pathways were a basis for the development
of numerous clinically relevant cancer therapies. The ef-
fects of different DNA damaging agents, as well as DDR
kinetics have been well characterized in mammalian cells
in vitro. However, very little is known about the amount of
actual DNA damage and the kinetics of DDR in tumors,
as well as normal tissues in vivo under antineoplastic
treatment.
Only few studies utilized individual patient material,
and initial DNA damage detection in patient tumor cells
was rarely performed. Use of lymphocytes irradiated out-
side of the patient (ex corpora) [1,2] revealed individual
patient heterogeneity and displayed more background
DNA damage in cancer patients vs. healthy individuals
[3,4]. Lymphocytes from human head and neck squa-
mous cell carcinoma (HNSCC) patients irradiated ex
corpora need more time to repair DNA double strand
breaks (dsbs) than lymphocytes from healthy donors [5]
and greater residual DNA damage was detected with
the single cell gel electrophoresis (comet) assay in these
patients [1,2].
Several studies show that addressing DDR in vivo can
lead to novel and clinically relevant insights. A non-invasive
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approach in mouse xenograft tumors revealed a second
wave of dsbs, marked by formation of phosphorylated his-
tone variant H2AX (γH2AX) foci, occurring 2 days after
the initial wave [6]. The cause of this second, unexpected
wave of dsbs is still unknown, with suspected causes of
radiation induced genetics instability and apoptosis [6].
DDR studies in ex vivo cultures from normal human
prostate tissue treated with ionizing radiation (IR) and
cytotoxic agents resulted in different responses of basal
versus luminal epithelial cells. The latter lacked γH2AX
foci formation completely, despite normal 53BP1 foci
formation [7]. Recently, some emphasis has been put on
in vivo DDR studies in patients: (i) Base excision- and
nucleotide excision repair (BER/NER) measurements in
human colorectal biopsies (neoplastic and adjacent nor-
mal tissue), revealed patient- but not tissue-specific re-
pair activity [8]. (ii) A study using normal epithelium of
human breast cancer patients concludes that S/G2 cell
cycle arrest during the course of radiation therapy (RT)
leads to greater use of homologous recombination (HR)
[9]. (iii) Analysis of HR defects in sporadic human breast
cancer patients showed low RAD51 scores being a strong
predictive marker of pathologic complete response to
chemotherapy [10]. Taken together, these studies suggest
that using DDR activity/proficiency as an in vivo readout
could lead to a more effective and appropriate treatment
of individuals.
Spontaneous tumors in companion animals like dogs
have been described to offer a unique opportunity as a
model for human cancer biology and translational clin-
ical research [11]. In contrast to many murine tumor
xenograft studies, canine tumors develop naturally and
grow over long periods of time in the setting of an intact
immune system. Human and canine tumors share many
similarities, such as inter-patient tumoral heterogeneity,
high incidence with age, similar biological behavior con-
cerning development of resistance and metastasis, and
comparable responses to antineoplastic agents. Further-
more, several studies indicated that factors of the DDR
pathways also affect both disease development and treat-
ment response in dogs [12-14]. As the evolution of most
cancers in dogs is shorter than that of humans, conclu-
sions from clinical studies can be drawn faster. To-
gether with the high amount of dog owners willing to
participate in clinical studies ([11,15] own experience),
the dog could serve as a model to explore the import-
ance of DDR and especially repair kinetics after antineo-
plastic treatment in vivo, thus offering opportunities for
both human and animal healthcare. However, so far
very little is known about DNA repair mechanisms and
DDR in the canine background. Herein, we will critic-
ally investigate the current knowledge of canine DDR
and discuss its potential to provide a basis as a model
for DDR in vivo.
Discussion
Animals spontaneously developing cancer within an intact
immune system are proposed to provide an excellent op-
portunity to investigate various aspects of cancer [16,17].
As opposed to experimental animals, companion animals
are genetically outbred and immunologically competent,
thus forming cancers that are more similar to human ones
in terms of patient size, cell kinetics and heterogeneity.
Moreover, clients (owners) are often willing to participate
in well-designed clinical trials. Dogs share physiological
and metabolic characteristics for most organ systems and
drugs with humans and are large enough for multiple
sampling opportunities, diagnostic and treatment in-
terventions. Over the last years, several consortia of
comparative oncology collaborations have formed and
are managed under the National Institutes of Health
(NIH)-National Cancer institute’s Comparative Oncology
Program (NCI-COP) in order to advance the study of
comparative tumor biology and clinical investigations. The
yearly cancer mortality rate for dogs < 10 years (deaths
due to cancer per 10,000 dog-years-at-risk in Swedish
dogs < 10 years) is high with 50% in over 350,000 insured
Swedish dogs and varies between breeds [18]. Over 1
million of pet dogs are diagnosed annually and managed
with cancer in the United States [16], and these patients
can often be entered in clinical trials when conventional
treatments do not meet the goals of the veterinary on-
cologist. Features of certain canine cancers are already
well characterized and show similarities with the human
situation [17,19]. In the following sections we critically
discuss, if - based on the current knowledge - the dog
can be proposed as a model to study DDR in vivo, as
well as point at missing links in this regard.
Are canine and human genomes similar enough to
comparatively study DNA damage response and repair?
The canine genome has been sequenced and is available
for studies identifying and associating genetically caused
diseases, which are of relevance for both animal and human
health. Bioinformatic analyses determined that around
94% of the dog genome belongs to regions of conserved
synteny between the dog, human, mouse and rat genomes
[20]. The euchromatic part of the canine genome is only
about 18% smaller than the human genome [21], but the
human and dog genomes differ largely in the chromosome
number (46 and 78, respectively). With respect to the
common ancestor of eutherian mammals (CAE, 2n = 42),
their genome is substantially rearranged. However, mouse
and rat genomes are also severely altered with respect to
the CAE genome, as they are highly rearranged and have
accumulated large numbers of nucleotide substitutions in
neutral sites [22]. Nonetheless, the canine gene products
seem to be more closely related to their human homologs
than those of mice. This suggests potentially higher
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functional similarity between canine and human proteins,
as well as indicates possibly better crossreactivity of hu-
man antibodies with canine proteins than with murine
ones, especially with respect to DDR proteins ([23]; own
observations). The antibody crossreactivity would be es-
pecially beneficial in case of functional studies. Humans
and dogs share an ancestrally related pathogenic basis
for cancer, with pathognomonic genetic changes being
conserved in both species [24]. As an example, the
BCR-ABL fusion gene could be detected with fluorescence
in situ hybridization (FISH) in canine chronic myeloge-
nous leukemia (CML) and chronic monocytic leukemia,
which is equivalent to the Philadelphia chromosome (with
the BCR-ABL fusion) in human CML showing equal
genomic break sites [24,25]. Besides similarities in protein-
coding regions, it is important to keep in mind that the
slight differences in the total amount of canine and hu-
man genetic material could result in different levels and
regulations of the micro (mi) RNAs, which are becom-
ing increasingly relevant. Apart from genetic alterations
of proteins, alterations in the miRNA coding regions
were shown to affect the regulation of DNA repair
[26,27]. Nevertheless, as it is well established that the
canine gene products are very similar to the human
ones, the functional read-outs of canine studies based
on the protein-coding regions do exhibit a high poten-
tial to result in deeper understanding and more accurate
predicting of the treatment-response. Involvement of
proteomic screens could provide additional insight in
this matter.
Are alterations in DNA damage response genes relevant
for the development of canine cancer?
In transformed tumor initiating cells with continuously
activated DDR, throughout mammalian species, deregu-
lated cell cycle check points and apoptosis mechanisms
often prevent an efficient halt of proliferation and cell
death induction. Amount of evidence clearly demon-
strates that the very similar misregulations occur in both
humans and dogs, resulting in genomic instability and
tumor progression. Abrogation of p53 function by muta-
tional and non-mutational mechanisms is one of the
most frequent tumor suppressor gene inactivations in
humans and domestic animals, while p53 dysfunction
and MDM2 (ubiquitin E3 ligase of p53) overexpression
play a central role in cancer progression [28-31]. Similarly,
p16 an important cell cycle regulator encoded by the gene
CDKN2A (Cyclin-dependent kinase inhibitors 2A; also
called multiple tumor suppressor 1) is often mutated in a
variety of human as well as canine cancers [32-34]. Loss of
nuclear p16 expression is a prognostic marker for human
melanoma and readily described in canine malignant
melanoma [32,35,36]. P21, a CDK inhibitor regulating cell
cycle progression is frequently down-regulated in both
human and canine tumors [37,38]. Consequently, the
extent of genomic instability has been described to be
equally comparable in certain canine and human tumor
types, such as osteosarcoma and colorectal cancer
[39,40]. Taken together present finding clearly indicate
that alterations in DDR genes are relevant for develop-
ment of canine cancer, however to shed more light on
tumor-associated defects, further investigations of differ-
ent canine tumor types with regard to their mutational
status and in particular the functional effects of mutations
are needed.
Can DNA damage response be compared and transferred
between the two species?
Only little is known about the DDR in the normal canine
background and its potential alterations in neoplastic tis-
sues. Nevertheless, as discussed bellow, few available stud-
ies indicate major similarities between human and canine
DDR pathways.
DDR initiation
Upon Minute virus of canines (MVC, an autonomous
parvovirus) infection classical DDR is triggered in canine
cells [23]. ATM activation leads to strong H2AX phos-
phorylation whereas ATR leads to RPA32 phosphoryl-
ation; both of which were also reported to take place in
human cells [23]. The MRN complex, which initially
recognizes DNA dsbs was additionally visualized. In
summary, the ATM-Mre11 axis is induced at the MVC
replication centers during infection. To our knowledge
the MVC study is the very first example of several import-
ant DDR proteins being detected with human antibodies
in canine cell lines. Thus suggesting high homology be-
tween the proteins of two species. Another study con-
firmed that the broadly used human antibody against
γH2AX is applicable in canine cells as well [41]. Al-
though the MVC study is the only investigation of DDR
initiation in canine cells, it: (i) implies similarities be-
tween human and canine response and (ii) represents
an important starting point for exploring the impact of
other stressors on canine cells.
DNA dsb repair
The amount of data directly comparing dsb repair kinetics
in human and canine cells is very limited. One study ad-
dressing the capacity of nuclear extracts to bind a linear
DNA probe (mimicking a DNA dsb) [42] revealed that
in comparison to human extracts, proteins from canine
extracts bind with a much lower affinity to linear DNA
(28-fold); proteins from hamster cell extracts exhibited
further decreased affinity [42]. The mechanism under-
lying this discrepancy is however not understood yet.
Recent comparison of the dsb repair kinetics by pulse
field gel electrophoresis (PFGE) after etoposide treatment
Grosse et al. BMC Cancer 2014, 14:203 Page 3 of 8
http://www.biomedcentral.com/1471-2407/14/203
indicated that the activity of fast non-homologous end
joining (NHEJ) repair is 25% lower in canine than human
cells, whereas the slow HR pathway seems to be similar.
Unfortunately, in this study the relative ratio of migrated
to non-migrated DNA was not taken into account, al-
though it differed significantly between the two species
[43]. NHEJ reduction in canine background potentially in-
dicates that DNA-PKcs, main kinase in this pathway,
could be more important in the primate background. In-
deed the intrinsic activity of this protein is 13-fold lower
in canine than in human fibroblasts [44]. The draw back
of this study however is that it utilized whole cell extracts,
in which the overall amount and activity of DNA-PKcs
could be influenced by interspecies differences in the
amount of cytosolic proteins or other components. An-
other potential consequence of increased DNA-PKcs
activity in human cells is that DNA-PKcs and its partner
Ku could bind faster to the DNA break ends in this
background. Consequently, the breaks would be pro-
tected faster and more often repaired via classical NHEJ
in human cells. As DNA-PKcs also regulates the activity
of backup-NHEJ pathways, these might be more active
in canine cells with less detectable DNA-PKcs [45]. If
NHEJ is less active in canine cells, then HR might be a
preferred dsb repair pathway.
In addition to above described findings of Park et al.
suggesting that HR could be equally active in both
species [43], mutations in different HR components have
been analyzed in tumor setting. As BRCA-mutations
lead to a higher risk of developing certain types of can-
cers in humans, the expression levels of these genes
were analyzed in dogs with mammary cancer. In canine
mammary carcinomas, BRCA2 and RAD51 show similar
regulations, which indicates similar functions (Figure 1).
In adenoma vs. normal samples, BRCA2/1 and RAD51
expression was reduced. In more advanced adenocarcin-
omas, however, BRCA2 and RAD51 were overexpressed
in about 50% of the cases. Overexpression was even
more pronounced in lymph node metastases [46]. Ex-
perimental studies are ongoing to clarify if these changes
are a direct response to altered genetic stability or if they
spontaneously occur during tumor formation. In English
Springer Spaniels with mammary tumors, BRCA1 and
BRCA2 genes seem to be involved in the development
of the tumor [19]. Furthermore, BRCA1 is possibly
involved in the malignant behavior [47]. However, the
results are sometimes conflicting and more cases have to
be analyzed to draw firm and general conclusions.
Taken together limited amount of data does not allow
drawing of strong conclusions about the similarities
between dsb repair in humans and dogs. However, there
are clear indications that certain pathways such as HR
might have higher degree of similarity between the two
species. This could be of particular interest in translational
Figure 1 DNA damages and corresponding repair mechanisms. Various exogenous and endogenous DNA damaging agents attack the DNA
on a daily basis. As a result many different types of DNA lesions are generated (green DNA strand with marked damage types (red or written)
and green boxes with names of damage types). In order to survive, the cells harbor a set of repair pathways (blue boxes). Important players mutated or
misregulated in both canine and human cancers are depicted in the lower part.
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research, particularly the one based on synthetic lethality.
To fully understand the significance and extent of differ-
ences between human and canine NHEJ pathway future
studies are needed such as, quantification of phosphor-
ylated DNA-PKcs-foci, NHEJ assays using a pathway-
specific substrate, determination of DNA-PKcs protein
levels with different antibodies and quantitative mass
spectrometry. The activity and efficiency of HR in canine
cells needs to be examined in further depth, among others
by comparing human and canine Rad51 foci kinetics after
the treatment with different genotoxic agents.
Base excision repair and nucleotide excision repair
Mechanisms like BER and NER have evolved to preserve
the fidelity of the genomic material, which is continu-
ously attacked by endogenous and exogenous stressors
(Figure 1). The efficiency of the formerly mentioned
repair pathways, especially BER, is thought to correlate
with lifespan. Though dogs live shorter than humans
(16.6 years vs. 90 years, respectively) [42], the BER cap-
acity of canine and human embryonic fibroblasts under
atmospheric oxygen tension (20%) is not significantly
different [43]. In contrast to BER, NER activity was shown
to be significantly different between the two species (25%
lower in dogs) [43]. Performing the assay under physio-
logical oxygen tension (3%), BER activity was also lower in
dog cells [43]. These two pathways could therefore vary
in activity between the two different species. However,
in the case of in vitro assays, the salt conditions and
redox potentials influenced the reactions massively,
which could explain observed repair differences between
the species [48]. Furthermore, cellular growth conditions
can influence the total BER protein expression [49], ren-
dering direct inter-species comparisons difficult. Interest-
ingly, the activity of DNA polymerase β, the key enzyme
in filling a single nucleotide gap during BER, was in-
creased in species with shorter lifespan [50]. Though these
findings point at intriguing similarities and differences
between human and canine excision pathways, as in case
of dsb repair, extensive work is needed to understand to
which extent DNA repair is comparable between the two
species.
In which tumors do we have sufficiently based potential
to compare DNA damage repair?
Breast cancer
Tumor gene expression studies of BRCA-mutations in
malignant canine mammary tumors have shown varied
results with under-expression of BRCA1 in malignant, as
well as over-expression of BRCA2 in metastatic tumors
[46,47]. As in women, germline mutations also showed a
significantly increased risk of mammary cancer develop-
ment in the examined breed of English Springer Spaniels
[18,19]. BRCA2 and Rad51 expression were proposed as
histologic criteria in canine breast cancer staging (Figure 1)
[46]. While little is known about the DDR in canine mam-
mary cancer, comparable BRCA2 and Rad51 misregula-
tions, point towards a high possibility of similarly altered
HR pathway in the two species.
Prostate cancer
Compared to men, the incidence of prostatic cancer in
dog is low. However, the spontaneous development of
the disease in dogs has awoken the interest to use dogs
as a comparative model for prostate cancer [51]. The
disease in dog behaves similarly to high-grade prostate
cancer in men and – although the highly aggressive vari-
ant is rather rare in elderly men - the model character can
be exploited for treatment strategies such as chemother-
apy, vascular targeting, radiation therapy approaches and
management of disseminated disease.
Osteosarcoma
Canine osteosarcoma has been shown in many studies
to be a valuable comparative model, as it has many simi-
larities on the genetic level, in clinical and biological be-
havior and in metastasis formation [52,53]. Case collection
is more rapid, as osteosarcoma is much more common in
dogs than in man. Common genetic and molecular alter-
ations affect p53, retinoblastoma protein (Rb), c-Met, GH
and IGF-1 [52]. So far, little is known about DNA repair in
canine osteosarcoma. In many DDR studies, the human
osteosarcoma cell line U2OS was used and in further stud-
ies findings should be compared with canine osteosarcoma
cell lines.
Skin cancer
Physical factors, such as cumulative exposure to DNA
damaging agents, such as UV-radiation, and viral factors,
such as papilloma-viruses, have been described as causa-
tive agents in canine cutaneous neoplasia. Canine skin
tumors may also be induced directly through genetic
mutations in factors such as p53 [54,55]. In two of the
common malignant tumors of the skin, squamous cell
carcinoma and melanoma genes and proteins regulating
the cell cycle and cell death are affected. The p53 pro-
tein was shown to solely localize to the cytoplasm in
many tumor cases [13]. P16 expression was significantly
reduced [32]. Both proteins usually cause cell cycle arrest
or delay, which provides the time for DNA repair or the
induction of apoptosis in the case of heavily damaged
cells. Therefore, misregulation of important tumor sup-
pressor genes leads to genomic instability and progression
of canine melanoma of the skin [32].
Hematologic cancer
Non-Hodgkin’s lymphoma (NHL) represents the fifth
leading cause of death due to cancer in humans and the
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high frequency of malignant lymphoma (7-24% of all ca-
nine tumors) in dogs continues to increase as well.
Chronic myelogenous leukemia (CML), sporadic Burkitt
lymphoma (BL) and chronic lymphocytic leukemia/small
lymphocytic lymphoma (CLL) are three well-characterized
hematologic cancers that are morphologically similar in
both species [24]. The common genetic mutations and
altered oncogene or tumor suppressor gene expression, as
well as signal transduction alterations (including N-ras,
p53, Rb, and p16 cyclin dependent kinase aberrations),
have been reported to occur similarly in human lymph-
omas as well as in dogs [14,56,57]. In human chronic mye-
logenous leukemia (CML), an aberrant BCR-ABL fusion
transcript is the hallmark of the disease [24]. The aber-
ration is seen in more than 90% of adult patients [58]. It
was demonstrated that expression of BCR-ABL leads to
the direct down-regulation of DNA-PKcs [59]. This
proteasome-dependent degradation leads to a marked
DNA repair deficiency and explains how secondary gen-
etic alterations accumulate in CML. In five cases of ca-
nine CML, BCR-ABL translocations could be detected
as well, affecting 11 – 34% of the cells [24]. Therefore,
tumorigenesis of CML seems to be similar to the human
malignancy. In the canine situation however, an add-
itional down-regulation of DNA-PKcs still has to be
verified.
In summary the five depicted tumor types are highly
adequate models to translationally study tumor biology
and treatment responses. We postulate that these tumors
can also be used to study the DDR in vivo. In many of
these tumors, cell cycle control proteins are altered, thus
indicating increased genomic instability and DDR defects
in spontaneously developing canine tumors.
Summary
In order to answer the question if studies in dogs have
potential and perspective to serve as an in vivo model
for DDR a positive outlook can be granted. Integrating
spontaneous canine tumor models has several important
advantages. Due to the high caseloads in veterinary clinics
and shorter lifespan, studies can be performed quite fast.
Cancers occurring in dogs and humans arise naturally
with age, in the background of an intact immune system.
They comprise many common features like histological
appearance, tumor genetics, molecular targets, biological
behavior and response to conventional therapies. More-
over, in many terms a canine model will even serve better
than the murine one to study DDR and its defects in vivo,
as in mice certain repair pathways seem to be less active
in comparison to the human mechanisms. Therefore, mice
have potentially a different emphasis and hierarchy of
DNA repair pathways [43]. As described above, rather lit-
tle is known about the DDR in canine cells and tissues.
However, the antibody cross-reactivities of the human and
canine proteins and the findings summarized in this article
clearly show that the DDR of dog cells is potentially highly
similar to human cells. In order to use canine tumor pa-
tients as models, the regulation and kinetics of the ca-
nine DDR will have to be studied more thoroughly at
the biochemical and cellular level, by gene and muta-
tional analyses as well as by global molecular pathway
studies aiming to elucidate the similarities and differ-
ences to human cancers. In this way, the dog as our
closest companion can help to better understand the
DDR in vivo and to verify new treatment strategies on
the DNA level in vivo.
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